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Results. We included 250 patients during the study period. The median age was 55 (19-91) years, 55.6% (139/250) were male, and 49.2% (123/250) were admitted in the intensive care unit (ICU). 77. 2% (193/250 ) had at least one comorbidity, with solid-organ malignancy (27.6%, 69/250) being the most common. Most patients had at least one invasive device, commonly a nasogastric tube (64.4%, 161/250) or mechanical ventilator (63.2%, 150/250). There was an increase in Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II score, qSOFA, and septic shock from baseline to 24 hours prior to colistin use (Table 1) . The most common site of infection was the respiratory tract (90.8%, 227/250). Majority of patients (78.8%, 197/250) had Acinetobacter baumannii infection of which 79.9% were extensively drug-resistant (XDR), susceptible only to colistin and amikacin or minocycline. Colistin was given for a mean of 12 (2-43) days, concomitant with meropenem in 96.4% (241/250). Most patients received piperacillin-tazobactam (59%, 142/250) and/or meropenem (58%, 138/250) within the same admission. Nephrotoxicity (30.8%, 77/250) was the most frequent adverse effect (Table 2) . Renal replacement therapy was needed in 6% (15/250) patients. Clinical success was seen in 61.2% (153/250) patients and overall mortality was 41.6% (104/250).
Conclusion. Colistin was frequently used in combination with a carbapenem for treatment of XDR-related respiratory infection or septic shock. Nephrotoxicity was a common adverse effect. The clinical success rate was modest and overall mortality was high.
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No reported disclosures. Background. Meropenem/vaborbactam (MV) is a carbapenem and boronic acid-based β-lactamase inhibitor combination product with potent in vitro activity against Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. As carbapenem resistance in Pseudomonas aeruginosa (PSA) is primarily driven by porin mutations, efflux pumps, or infrequently by metallo-β-lactamases, vaborbactam is not expected to improve the in vitro activity of meropenem (MEM) against this pathogen.
Comparative In Vitro
However, limited data currently exists assessing the comparative in vitro activity of MEM and MV. The purpose of this study was to compare the in vitro activity of MV and MEM against a large real-world sample of clinical isolates of PSA where both MV and MEM are routinely tested on all isolates.
Methods. All cultures from patient infections with PSA from May 2018 to February 2019 at Michigan Medicine were included. Minimum inhibitory concentrations (MICs) were determined using TREK broth microdilution panels and isolates were considered susceptible to MV if the MIC was ≤4 mg/L and MEM if the MIC was ≤2 mg/L. Results. A total of 2,967 isolates of PSA from clinical specimens were included. 80.5% of isolates were susceptible to MEM (MIC 50 ≤1 mg/L and MIC 90 8 mg/L, range ≤1 to >32 mg/L) at a breakpoint of ≤2 mg/L and 86.3% at a breakpoint of ≤4 mg/L; whereas 90.8% of isolates were susceptible to MV (MIC 50 ≤1 mg/L and MIC 90 4 mg/L, range ≤1 to >8 mg/L). Of those displaying MEM MIC >2 mg/L, 53% (n = 308) were susceptible to MV. Of those displaying MEM MIC >4 mg/L, 33.7% (n = 137) were susceptible to MV. Although the majority of MIC discordances in MEM-R/MV-S isolates were 1-2 doubling dilutions, 52 (38%) isolates had their meropenem MIC decreased ≥3 doubling dilutions by the addition of vaborbactam suggesting significant inhibitory activity (Table 1) .
Conclusion. We found a surprising number of PSA isolates with discordant MV and MEM susceptibility at Michigan Medicine. Further exploration of mechanisms of meropenem resistance in these isolates is warranted.
Disclosures. All authors:
No reported disclosures. Methods. All cultures from patient infections with PSA from May 2018 to February 2019 at Michigan Medicine were included. Minimum inhibitory concentrations (MICs) for all β-lactams were determined using TREK broth microdilution panels and isolates were considered susceptible to CZA if the MIC was ≤8 mg/L and CT if the MIC was ≤4 mg/L. Results. A total of 2,972 isolates of PSA from clinical specimens were included. Table 1 compares CZA and CT susceptibility, MIC 50 , MIC 90 , and MIC range for all isolates including those displaying resistance to various β-lactams. Among all isolates of PSA, CZA (96.2% susceptible) was slightly more active than CT (94.2%) and both agents were ~10% more active than the closest comparator (ceftazidime, 86.6%). In vitro activity of cefepime, piperacillin/tazobactam, and meropenem were 84.8%, 78%, and 80.3%, respectively. The activity of both CZA and CT dropped significantly among isolates with pan-β-lactam resistance (i.e., resistance to all conventional anti-pseudomonal β lactams, PBR) but CZA remained more active than CT (59.4% vs. 41.5%, P < 0.001). Of isolates displaying resistance to CT, 84 (48.6%) were susceptible to CZA. However, of those with resistance to CZA, only 24 (21.2%) were susceptible to CT (Table 2) .
In Vitro
Conclusion. CZA was the most active β-lactam against PSA isolates at Michigan Medicine. Among PSA with PBR, CZA demonstrated superior activity compared with CT. Additionally, a significant number of isolates with resistance to CT were susceptible
